Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis.

Gan-Shen Yu,Yin Xu,Ze-Xuan Su,Chen-Feng Bu,Cai-Yong Lai

doi:10.7314/apjcp.2015.16.11.4665

Abstract

The aim of this study was to assess the diagnostic value of RASSF1A methylation in renal cell carcinoma. Systematically search were performed using the Pubmed, ProQest and Web of Science for all articles on the association between RASSF1A methylation and renal cell carcinoma before 15 April 2015. After the filtration, 13 studies involving 677 cases and 497 controls met our criteria. Our meta-analysis suggested that hypermethylation of RASSF1A gene was associated with the increased risk of RCC(OR:4.14, 95%CI:1.06-16.1). Stratified analyses showed a similar risk in qualitative detection method(OR:28.4, 95%CI:10.2-79.6), body fluid sample(OR:12.8, 95%CI:5.35-30.8), and American(OR:10.5, 95%CI:1.97-55.9). Our result identified that RASSF1A methylation had a strong potential in prediction the risk of Renal cell carcinoma.

Highlights

With the advent of the aging society, cancer has became one of the serious threats to human health and it is the second leading cause of death, only surpassed by heart diseases
To further confirm the diagnostic value of RAS association domain family 1A gene (RASSF1A) methylation in Renal cell carcinoma (RCC), we conducted a detail meta-analysis in 13 eligible studies involving 677 cases and 497 controls. It suggested that hypermethylation of RASSF1A might be a risk factor in renal cell carcinoma (OR:4.14, 95%confidential intervals (CIs):1.06-16.1)
The morphologically normal tissues in control group were collected from specimens being adjacent to neoplasm. we were tempted to speculate that these “normal tissue” had acquired genetic or epigenetic changes trending to tumorigenesis

Summary

Introduction

With the advent of the aging society, cancer has became one of the serious threats to human health and it is the second leading cause of death, only surpassed by heart diseases. The incidence of kidney cancer ranks third in human urinary system tumors, with more than 61, 000 new cases each year and more than 14, 000 deaths per year (Siegel et al, 2015). Most of patients with RCC can be symptom-free in the early stage, 20-30% of them have already developed to metastases at the time of diagnosis (Lam et al, 2005).

Objectives

Methods

Results

Conclusion